Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
In this phase I study we will characterize the safety, tolerability, maximum tolerated dose
and dose-limiting toxicity of weekly bolus topotecan when administered in combination with
two different dosing schedules of carboplatin. We will also evaluate any antitumor activity
of these combination regimens.